Advanced BioHealing Aquires Rights and Assets for Dermagraft® and TransCyte®
Advanced BioHealing, Inc. (ABH, New York, NY) announces the company has concluded the acquisition of the assets and rights to the advanced wound care products Dermagraft® and TransCyte® from Smith & Nephew (Largo, Fla). Both products have been approved for marketing in the United States and other countries. The transaction transfers to ABH the assets and rights relating to these products. Financial terms were not disclosed.
Dermagraft is indicated for use in the treatment of full-thickness diabetic foot ulcers. The product was approved for sale in the United States in 2001. Dermagraft is a cryopreserved human fibroblast-derived dermal substitute. It is supplied frozen in a clear bag containing 1 piece (approximately 2" x 3") for single-use application.
Visit http://www.AdvancedBioHealing.com for more information.
Bridge PTS Offers Preclinical Testing Services Bridge Preclinical Testing Services (Bridge PTS, San Antonio, Tex) offers a comprehensive line of preclinical animal models of acute, semi-chronic, and infected wounds. The models include debridement, ischemia, diabetes, and catheter- and other device-related infections. These models have been used to test hundreds of therapeutic products ranging from medical devices, to chemical and peptide drugs, to enzymes and grafts. The company also has expertise in working with infectious microbial and fungal strains.
Bridge PTS is dedicated to the research and development of new wound healing models and device-related infection. The company is pursuing both internal and collaborative research projects that will focus on unique species ranging from mammals to insects. The company is currently working to validate these new model systems.
Call 210-842-5890 or email paul.attar@bridgepts.com for more information.
|
